Overall rank by patents
#44,559
Across all tracked assignees
USPTO PatentsView assignee record - 5 granted patents across 13 technology areas, active 2020–2024. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61Q (SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS).
The verdict
Anomera holds 5 US patents across 13 technology areas, rank #44,559 of 50,000 tracked assignees.
Anomera Inc. has been granted 5 US utility patents between 2020 and 2024, placing Anomera Inc. at rank #44,559 across all assignees tracked by PlainPatent. This portfolio spans 13 distinct Cooperative Patent Classification (CPC) subclasses, averaging 21.4 claims per patent with primary concentration in A61Q (SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS). As a Foreign Corporation, Anomera Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Anomera sits between Angioclinic Ag (5 patents, rank #44,555) and Antares Vision S.p.a. (5 patents, rank #44,563) - the closest US assignees by grant volume. The composite Innovation Score of 36.2/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Historical data spans 2020 through 2024, with 5 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Anomera Inc.'s 21.4 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while concentration in 13 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Anomera Inc. against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
ANGIOCLINIC AG
5 patents
ANHUI MAOXIN HOME CRAFTS CO., LTD.
5 patents
ANIXA DIAGNOSTICS CORPORATION
5 patents
ANKOM TECHNOLOGY CORPORATION
5 patents
ANOVENT PHARMACEUTICAL (U.S.), LLC
5 patents
ANQING MEDICAL CO., LTD.
5 patents
ANSALDO ENERGIA S.P.A.
5 patents
ANTARES VISION S.p.A.
5 patents
ANOMERA INC.
5 patents
What this shows Anomera holds 5 patents at rank #44,559, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #44,559 in granted patent volume.
Other assignees with the most granted patents in Anomera's primary technology class.
Anomera's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
36 Top 47% higher than 53% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2020 | 1 | 20.0% |
| 2021 | 2 | 40.0% |
| 2022 | 1 | 20.0% |
| 2024 | 1 | 20.0% |
Top 13 of 13 technology areas
Overall rank by patents
#44,559
Across all tracked assignees
36.2 out of 100
How to use this portfolio
Anomera's 5 grants land it in the top 47% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.